{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T23:43:09Z","timestamp":1794440589917,"version":"4.9.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82070217"],"award-info":[{"award-number":["82070217"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81873427"],"award-info":[{"award-number":["81873427"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010877","name":"Shenzhen Science and Technology Innovation Commission","doi-asserted-by":"publisher","award":["GJHZ20220913143405011"],"award-info":[{"award-number":["GJHZ20220913143405011"]}],"id":[{"id":"10.13039\/501100010877","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The prognostic implications of TP53 alterations in patients with relapsed or refractory (r\/r) aggressive B-cell non-Hodgkin lymphoma (B-NHL) treated with chimeric antigen receptor (CAR) T-cell therapy remain inadequately characterized, particularly with respect to long-term outcomes. We report extended follow-up (median: 77.77 months) of 122 patients with r\/r B-NHL who received either dual-targeted CD19\/CD22 CAR-T-cell therapy alone (cohort A,\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200965) or following sequential autologous stem cell transplantation (ASCT; cohort B,\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200957). TP53 alterations were identified in 59 patients (48.4%). Within both cohorts, overall survival (OS) and progression-free survival (PFS) did not significantly differ between the TP53-altered subgroup and the wild-type subgroup (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&gt;0.05). Notably, compared with CAR-T-cell monotherapy, the sequential ASCT-CAR-T-cell approach (cohort B) was associated with improved 5-year OS (70.2% vs. 40.0%) and PFS (64.9% vs. 35.4%). The 5-year cumulative incidence of nonrelapse mortality was 10.7% overall (9.2% in cohort A vs. 12.3% in cohort B). Secondary malignancies occurred in 2.5% of patients, whereas serious infection-related events beyond 3 months post-infusion were observed in 13.6%, supporting a favorable long-term safety profile. Multivariate analysis identified treatment options and the presence of bulky disease as independent adverse prognostic factors for OS and PFS. These findings suggest that dual-target CD19\/CD22 CAR-T-cell therapy, particularly when integrated with ASCT, may mitigate the adverse prognostic influence of TP53 alterations, offering sustained clinical benefit with manageable long-term toxicity in r\/r aggressive B-NHL.\n                  <\/jats:p>","DOI":"10.1038\/s41392-025-02571-7","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:03:41Z","timestamp":1770941021000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Long-term follow-up demonstrates the curative potential of dual CD19\/CD22 CAR-T-cell therapy alone or combined with autologous stem cell transplantation in TP53-altered relapsed\/refractory B-cell non-Hodgkin lymphoma"],"prefix":"10.1038","volume":"11","author":[{"given":"Zekai","family":"Mao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinghuan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fankai","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yicheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6435-9368","authenticated-orcid":false,"given":"Jia","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,13]]},"reference":[{"key":"2571_CR1","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/cac2.12520","volume":"44","author":"B Song","year":"2024","unstructured":"Song, B. et al. Cell fate regulation governed by p53: friends or reversible foes in cancer therapy. Cancer Commun. 44, 297\u2013360 (2024).","journal-title":"Cancer Commun."},{"key":"2571_CR2","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41392-023-01358-y","volume":"8","author":"R Shen","year":"2023","unstructured":"Shen, R. et al. Simplified algorithm for genetic subtyping in diffuse large B-cell lymphoma. Signal Transduct. Target Ther. 8, 145 (2023).","journal-title":"Signal Transduct. Target Ther."},{"key":"2571_CR3","doi-asserted-by":"crossref","unstructured":"Liu, W. et al. Combinational therapy of CAR T-cell and HDT\/ASCT demonstrates impressive clinical efficacy and improved CAR T-cell behavior in relapsed\/refractory large B-cell lymphoma. J. Immunother. Cancer 12, e008857 (2024).","DOI":"10.1136\/jitc-2024-008857"},{"key":"2571_CR4","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.critrevonc.2015.08.006","volume":"97","author":"TX Lu","year":"2016","unstructured":"Lu, T. X. et al. TP53 dysfunction in diffuse large B-cell lymphoma. Crit. Rev. Oncol. Hematol. 97, 47\u201355 (2016).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"2571_CR5","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1038\/s41375-022-01634-w","volume":"36","author":"Y Hong","year":"2022","unstructured":"Hong, Y. et al. APR-246 triggers ferritinophagy and ferroptosis of diffuse large B-cell lymphoma cells with distinct TP53 mutations. Leukemia 36, 2269\u20132280 (2022).","journal-title":"Leukemia"},{"key":"2571_CR6","doi-asserted-by":"publisher","first-page":"4910","DOI":"10.1158\/1078-0432.CCR-21-0464","volume":"27","author":"T Liu","year":"2021","unstructured":"Liu, T. et al. Pharmacologic targeting of Mcl-1 induces mitochondrial dysfunction and apoptosis in B-cell lymphoma cells in a TP53- and BAX-dependent manner. Clin. Cancer Res. 27, 4910\u20134922 (2021).","journal-title":"Clin. Cancer Res."},{"key":"2571_CR7","doi-asserted-by":"crossref","unstructured":"Crump, M. et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood 130, 1800\u20131808 (2017).","DOI":"10.1182\/blood-2017-03-769620"},{"key":"2571_CR8","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/S1470-2045(17)30444-8","volume":"18","author":"A Chiappella","year":"2017","unstructured":"Chiappella, A. et al. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a phase 3 trial. Lancet Oncol. 18, 1076\u20131088 (2017).","journal-title":"Lancet Oncol."},{"key":"2571_CR9","doi-asserted-by":"publisher","first-page":"e541","DOI":"10.3324\/haematol.2018.194399","volume":"103","author":"CW Eskelund","year":"2018","unstructured":"Eskelund, C. W. et al. Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma. Haematologica 103, e541\u2013e543 (2018).","journal-title":"Haematologica"},{"key":"2571_CR10","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/S1470-2045(21)00638-0","volume":"23","author":"ML Wang","year":"2022","unstructured":"Wang, M. L. et al. Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients with mantle cell lymphoma (WINDOW-1): A phase 2 trial. Lancet Oncol. 23, 406\u2013415 (2022).","journal-title":"Lancet Oncol."},{"key":"2571_CR11","doi-asserted-by":"publisher","first-page":"4482","DOI":"10.1182\/blood-2024-202789","volume":"144","author":"Y Fang","year":"2024","unstructured":"Fang, Y. et al. Mechanism and updated results of selinexor combined with salvage regimen for refractory diffuse large B-cell lymphoma patients with TP53 alterations. Blood 144, 4482 (2024).","journal-title":"Blood"},{"key":"2571_CR12","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa2116133","volume":"386","author":"FL Locke","year":"2022","unstructured":"Locke, F. L. et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N. Engl. J. Med. 386, 640\u2013654 (2022).","journal-title":"N. Engl. J. Med."},{"key":"2571_CR13","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1200\/JCO.21.02143","volume":"40","author":"R Shouval","year":"2022","unstructured":"Shouval, R. et al. Impact of TP53 genomic alterations in large B-cell lymphoma treated with CD19-CAR T-cell therapy. J. Clin. Oncol. 40, 369\u2013381 (2022).","journal-title":"J. Clin. Oncol."},{"key":"2571_CR14","doi-asserted-by":"crossref","unstructured":"Porpaczy, E. et al. Influence of TP53 mutation on survival of diffuse large B-cell lymphoma in the CAR T-cell era. Cancers 13, 5592 (2021).","DOI":"10.3390\/cancers13225592"},{"key":"2571_CR15","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1038\/s41591-022-01731-4","volume":"28","author":"SS Neelapu","year":"2022","unstructured":"Neelapu, S. S. et al. Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: The phase 2 ZUMA-12 trial. Nat. Med. 28, 735\u2013742 (2022).","journal-title":"Nat. Med."},{"key":"2571_CR16","doi-asserted-by":"publisher","first-page":"747.e741","DOI":"10.1016\/j.jtct.2023.08.026","volume":"29","author":"M Bastos-Oreiro","year":"2023","unstructured":"Bastos-Oreiro, M. et al. Impact of SCHOLAR-1 criteria on CAR T-cell therapy efficacy in aggressive B lymphoma: a real-world study. Transplant. Cell. Ther. 29, 747.e741\u2013747.e710 (2023).","journal-title":"Transplant. Cell. Ther."},{"key":"2571_CR17","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1002\/ajh.27548","volume":"100","author":"SK Thiruvengadam","year":"2025","unstructured":"Thiruvengadam, S. K. et al. Outcomes of CD19 CAR T in transformed indolent lymphoma compared to de novo aggressive large B-cell lymphoma. Am. J. Hematol. 100, 236\u2013248 (2025).","journal-title":"Am. J. Hematol."},{"key":"2571_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-024-01765-w","volume":"22","author":"KX Du","year":"2024","unstructured":"Du, K. X. et al. Identifying high-risk TP53-mutated diffuse large B-cell lymphoma and exploring underlying mechanisms. Cell Commun. Signal. 22, 401 (2024).","journal-title":"Cell Commun. Signal."},{"key":"2571_CR19","first-page":"40","volume":"136","author":"C Jacobson","year":"2020","unstructured":"Jacobson, C. et al. Long-term survival and B-cell recovery after axicabtagene ciloleucel for refractory large B-cell lymphoma. Blood 136, 40\u201342 (2020).","journal-title":"Blood"},{"key":"2571_CR20","doi-asserted-by":"publisher","first-page":"6928","DOI":"10.1182\/blood-2023-181351","volume":"142","author":"Z Yan","year":"2023","unstructured":"Yan, Z. et al. Efficacy and safety of axicabtagene ciloleucel in Chinese patients with relapsed\/refractory NHL. Blood 142, 6928 (2023).","journal-title":"Blood"},{"key":"2571_CR21","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1016\/j.jcyt.2024.07.011","volume":"26","author":"B Xue","year":"2024","unstructured":"Xue, B. et al. CD19 CAR-T treatment shows limited efficacy in r\/r DLBCL with double expression and TP53 alterations. Cytotherapy 26, 1465\u20131471 (2024).","journal-title":"Cytotherapy"},{"key":"2571_CR22","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1182\/blood.2024026401","volume":"145","author":"W Yu","year":"2025","unstructured":"Yu, W. et al. A phase 1 trial of prizloncabtagene autoleucel, a CD19\/CD20 CAR T-cell therapy for relapsed\/refractory B-cell lymphoma. Blood 145, 1526\u20131535 (2025).","journal-title":"Blood"},{"key":"2571_CR23","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1158\/2326-6066.CIR-20-0675","volume":"9","author":"G Wei","year":"2021","unstructured":"Wei, G. et al. CD19\/CD22 dual-targeted CAR T-cell therapy for relapsed\/refractory aggressive B-cell lymphoma. Cancer Immunol. Res. 9, 1061\u20131070 (2021).","journal-title":"Cancer Immunol. Res."},{"key":"2571_CR24","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1038\/s41591-021-01436-0","volume":"27","author":"JY Spiegel","year":"2021","unstructured":"Spiegel, J. Y. et al. CAR T cells with dual targeting of CD19\/CD22 in recurrent or refractory B-cell malignancies: a phase 1 trial. Nat. Med. 27, 1419\u20131431 (2021).","journal-title":"Nat. Med."},{"key":"2571_CR25","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1182\/blood-2020-140907","volume":"136","author":"C Tong","year":"2020","unstructured":"Tong, C. et al. Optimized tandem CD19\/CD20 CAR T-cells in refractory\/relapsed B-cell lymphoma. Blood 136, 1632\u20131644 (2020).","journal-title":"Blood"},{"key":"2571_CR26","first-page":"2470","volume":"141","author":"C Roddie","year":"2023","unstructured":"Roddie, C. et al. Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in relapsed\/refractory LBCL. Blood 141, 2470\u20132482 (2023).","journal-title":"Blood"},{"key":"2571_CR27","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1038\/s41591-020-1081-3","volume":"26","author":"NN Shah","year":"2020","unstructured":"Shah, N. N. et al. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B-cell malignancies: a phase 1 trial. Nat. Med. 26, 1569\u20131575 (2020).","journal-title":"Nat. Med."},{"key":"2571_CR28","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41392-022-00924-0","volume":"7","author":"J Wei","year":"2022","unstructured":"Wei, J. et al. Outcomes of aggressive B-cell lymphoma with TP53 alterations treated with CAR T-cell cocktail alone or with ASCT. Signal Transduct. Target. Ther. 7, 101 (2022).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2571_CR29","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.176","volume":"10","author":"J Wei","year":"2020","unstructured":"Wei, J. et al. Long-term outcomes of relapsed\/refractory double-hit lymphoma treated with CD19\/22 CAR T-cell cocktail therapy. Clin. Transl. Med. 10, e176 (2020).","journal-title":"Clin. Transl. Med."},{"key":"2571_CR30","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s00262-024-03855-7","volume":"74","author":"J Wu","year":"2024","unstructured":"Wu, J. et al. CAR T-cell therapy after autologous HSCT in r\/r CNS lymphoma. Cancer Immunol. Immunother. 74, 17 (2024).","journal-title":"Cancer Immunol. Immunother."},{"key":"2571_CR31","doi-asserted-by":"publisher","first-page":"910.e911","DOI":"10.1016\/j.jtct.2021.08.012","volume":"27","author":"Y Cao","year":"2021","unstructured":"Cao, Y. et al. CD19\/CD22 CAR T-cell cocktail therapy following autologous transplantation in r\/r aggressive B-cell lymphoma. Transplant. Cell. Ther. 27, 910.e911\u2013910.e911 (2021).","journal-title":"Transplant. Cell. Ther."},{"key":"2571_CR32","first-page":"103477","volume":"73","author":"Y Liu","year":"2025","unstructured":"Liu, Y. et al. CAR T-cell therapy combined with autologous HSCT in r\/r Burkitt lymphoma. Curr. Res. Transl. Med. 73, 103477 (2025).","journal-title":"Curr. Res. Transl. Med."},{"key":"2571_CR33","doi-asserted-by":"publisher","first-page":"3581","DOI":"10.1200\/JCO.23.02786","volume":"42","author":"MD Jain","year":"2024","unstructured":"Jain, M. D. et al. Five-year follow-up of standard-of-care axicabtagene ciloleucel for LBCL: US CAR T consortium results. J. Clin. Oncol. 42, 3581\u20133592 (2024).","journal-title":"J. Clin. Oncol."},{"key":"2571_CR34","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1182\/bloodadvances.2023011532","volume":"8","author":"A Ghobadi","year":"2024","unstructured":"Ghobadi, A. et al. Outcomes of subsequent therapy after second-line axicabtagene ciloleucel or SOC in ZUMA-7. Blood Adv. 8, 2982\u20132990 (2024).","journal-title":"Blood Adv."},{"key":"2571_CR35","first-page":"2307","volume":"141","author":"SS Neelapu","year":"2023","unstructured":"Neelapu, S. S. et al. Five-year follow-up of ZUMA-1 supports curative potential of axicabtagene ciloleucel. Blood 141, 2307\u20132315 (2023).","journal-title":"Blood"},{"key":"2571_CR36","doi-asserted-by":"publisher","unstructured":"Zhang, X. et al. Long-term outcomes of CD19\/22 CAR T-cell therapy alone or with ASCT in r\/r DLBCL. Blood Cancer Discov. https:\/\/doi.org\/10.1158\/2643-3230.BCD-24-0317 (2025).","DOI":"10.1158\/2643-3230.BCD-24-0317"},{"key":"2571_CR37","doi-asserted-by":"crossref","unstructured":"Zhang, X. et al. Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 high-risk B-ALL patients. Blood Adv. 4, 2325\u20132338 (2020).","DOI":"10.1182\/bloodadvances.2020001466"},{"key":"2571_CR38","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377, 2531\u20132544 (2017).","journal-title":"N. Engl. J. Med."},{"key":"2571_CR39","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1182\/blood.2023020621","volume":"143","author":"S Ghorashian","year":"2024","unstructured":"Ghorashian, S. et al. CD19\/CD22 targeting with cotransduced CAR T cells to prevent antigen-negative relapse in B-ALL. Blood 143, 118\u2013123 (2024).","journal-title":"Blood"},{"key":"2571_CR40","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1056\/NEJMoa2313812","volume":"390","author":"Y Hu","year":"2024","unstructured":"Hu, Y. et al. Sequential CD7 CAR T-cell therapy and allogeneic HSCT without GVHD prophylaxis. N. Engl. J. Med. 390, 1467\u20131480 (2024).","journal-title":"N. Engl. J. Med."},{"key":"2571_CR41","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1038\/s41591-024-03084-6","volume":"30","author":"DM Cordas Dos Santos","year":"2024","unstructured":"Cordas Dos Santos, D. M. et al. Nonrelapse mortality after CAR T-cell therapy: a systematic review and meta-analysis. Nat. Med. 30, 2667\u20132678 (2024).","journal-title":"Nat. Med."},{"key":"2571_CR42","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1001\/jamaoncol.2024.5412","volume":"11","author":"SA Patel","year":"2025","unstructured":"Patel, S. A. et al. Second primary cancer after CAR T-cell therapy: a review. JAMA Oncol. 11, 174\u2013181 (2025).","journal-title":"JAMA Oncol."},{"key":"2571_CR43","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1182\/blood.2018889931","volume":"133","author":"M Pascual","year":"2019","unstructured":"Pascual, M. et al. PD-1\/PD-L1 checkpoint and p53 loss promote tumor progression in ABC-DLBCL. Blood 133, 2401\u20132412 (2019).","journal-title":"Blood"},{"key":"2571_CR44","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","volume":"124","author":"DW Lee","year":"2014","unstructured":"Lee, D. W. et al. Current concepts in diagnosis and management of cytokine release syndrome. Blood 124, 188\u2013195 (2014).","journal-title":"Blood"},{"key":"2571_CR45","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.annonc.2020.10.478","volume":"32","author":"ML Schubert","year":"2021","unstructured":"Schubert, M. L. et al. Side-effect management of CAR T-cell therapy. Ann. Oncol. 32, 34\u201348 (2021).","journal-title":"Ann. Oncol."},{"key":"2571_CR46","doi-asserted-by":"publisher","first-page":"582","DOI":"10.6004\/jnccn.2024.0057","volume":"22","author":"JA Thompson","year":"2024","unstructured":"Thompson, J. A. et al. NCCN Guidelines\u00ae Insights: Management of immunotherapy-related toxicities, version 2.2024. J. Natl. Compr. Cancer Netw. 22, 582\u2013592 (2024).","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"2571_CR47","doi-asserted-by":"publisher","first-page":"e2461683","DOI":"10.1001\/jamanetworkopen.2024.61683","volume":"8","author":"L Camacho-Arteaga","year":"2025","unstructured":"Camacho-Arteaga, L. et al. Late adverse events after CAR T-cell therapy for aggressive B-cell lymphoma. JAMA Netw. Open 8, e2461683 (2025).","journal-title":"JAMA Netw. Open"},{"key":"2571_CR48","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1200\/JCO-25-00668","volume":"43","author":"SS Neelapu","year":"2025","unstructured":"Neelapu, S. S. et al. Five-year follow-up analysis of ZUMA-5: axicabtagene ciloleucel in r\/r indolent NHL. J. Clin. Oncol. 43, 3573\u20133577 (2025).","journal-title":"J. Clin. Oncol."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02571-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02571-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02571-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:03:44Z","timestamp":1770941024000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02571-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,13]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2571"],"URL":"https:\/\/doi.org\/10.1038\/s41392-025-02571-7","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,13]]},"assertion":[{"value":"28 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"53"}}